1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs c...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Antimicrobial agents and chemotherapy Ročník 41; číslo 5; s. 1082
Hlavní autoři:	Daluge, S M, Good, S S, Faletto, M B, Miller, W H, St Clair, M H, Boone, L R, Tisdale, M, Parry, N R, Reardon, J E, Dornsife, R E, Averett, D R, Krenitsky, T A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.05.1997
Témata:	Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - metabolism Adenosine Deaminase - metabolism Administration, Oral Animals Anti-HIV Agents - blood Anti-HIV Agents - chemistry Anti-HIV Agents - pharmacokinetics Anti-HIV Agents - urine Antiviral Agents - blood Antiviral Agents - pharmacokinetics Area Under Curve Biotransformation Cells, Cultured Dideoxynucleosides - blood Dideoxynucleosides - chemistry Dideoxynucleosides - pharmacokinetics Dideoxynucleosides - urine Drug Resistance, Microbial Female Half-Life HIV-1 - drug effects Humans Injections, Intravenous Macaca fascicularis Male Rats Structure-Activity Relationship
ISSN:	0066-4804
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs containing a cyclopentene substitution for the 2'-deoxyriboside of natural deoxynucleosides, optimizing in vitro anti-HIV potency, oral bioavailability, and central nervous system (CNS) penetration. 1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT). 1592U89 showed minimal cross-resistance (approximately twofold) with AZT and other approved HIV reverse transcriptase (RT) inhibitors. 1592U89 was synergistic in combination with AZT, the nonnucleoside RT inhibitor nevirapine, and the protease inhibitor 141W94 in MT4 cells against HIV-1 (IIIB). 1592U89 was anabolized intracellularly to its 5'-monophosphate in CD4+ CEM cells and in PBLs, but the di- and triphosphates of 1592U89 were not detected. The only triphosphate found in cells incubated with 1592U89 was that of the guanine analog (-)-carbovir (CBV). However, the in vivo pharmacokinetic, distribution, and toxicological profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM). 1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines. 1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT. Having demonstrated an excellent preclinical profile, 1592U89 has progressed to clinical evaluation in HIV-infected patients.
AbstractList	1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs containing a cyclopentene substitution for the 2'-deoxyriboside of natural deoxynucleosides, optimizing in vitro anti-HIV potency, oral bioavailability, and central nervous system (CNS) penetration. 1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT). 1592U89 showed minimal cross-resistance (approximately twofold) with AZT and other approved HIV reverse transcriptase (RT) inhibitors. 1592U89 was synergistic in combination with AZT, the nonnucleoside RT inhibitor nevirapine, and the protease inhibitor 141W94 in MT4 cells against HIV-1 (IIIB). 1592U89 was anabolized intracellularly to its 5'-monophosphate in CD4+ CEM cells and in PBLs, but the di- and triphosphates of 1592U89 were not detected. The only triphosphate found in cells incubated with 1592U89 was that of the guanine analog (-)-carbovir (CBV). However, the in vivo pharmacokinetic, distribution, and toxicological profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM). 1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines. 1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT. Having demonstrated an excellent preclinical profile, 1592U89 has progressed to clinical evaluation in HIV-infected patients. 1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs containing a cyclopentene substitution for the 2'-deoxyriboside of natural deoxynucleosides, optimizing in vitro anti-HIV potency, oral bioavailability, and central nervous system (CNS) penetration. 1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT). 1592U89 showed minimal cross-resistance (approximately twofold) with AZT and other approved HIV reverse transcriptase (RT) inhibitors. 1592U89 was synergistic in combination with AZT, the nonnucleoside RT inhibitor nevirapine, and the protease inhibitor 141W94 in MT4 cells against HIV-1 (IIIB). 1592U89 was anabolized intracellularly to its 5'-monophosphate in CD4+ CEM cells and in PBLs, but the di- and triphosphates of 1592U89 were not detected. The only triphosphate found in cells incubated with 1592U89 was that of the guanine analog (-)-carbovir (CBV). However, the in vivo pharmacokinetic, distribution, and toxicological profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM). 1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines. 1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT. Having demonstrated an excellent preclinical profile, 1592U89 has progressed to clinical evaluation in HIV-infected patients.1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs containing a cyclopentene substitution for the 2'-deoxyriboside of natural deoxynucleosides, optimizing in vitro anti-HIV potency, oral bioavailability, and central nervous system (CNS) penetration. 1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT). 1592U89 showed minimal cross-resistance (approximately twofold) with AZT and other approved HIV reverse transcriptase (RT) inhibitors. 1592U89 was synergistic in combination with AZT, the nonnucleoside RT inhibitor nevirapine, and the protease inhibitor 141W94 in MT4 cells against HIV-1 (IIIB). 1592U89 was anabolized intracellularly to its 5'-monophosphate in CD4+ CEM cells and in PBLs, but the di- and triphosphates of 1592U89 were not detected. The only triphosphate found in cells incubated with 1592U89 was that of the guanine analog (-)-carbovir (CBV). However, the in vivo pharmacokinetic, distribution, and toxicological profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM). 1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines. 1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT. Having demonstrated an excellent preclinical profile, 1592U89 has progressed to clinical evaluation in HIV-infected patients.
Author	Averett, D R Boone, L R Miller, W H Tisdale, M St Clair, M H Dornsife, R E Good, S S Reardon, J E Faletto, M B Parry, N R Daluge, S M Krenitsky, T A
Author_xml	– sequence: 1 givenname: S M surname: Daluge fullname: Daluge, S M email: susan_daluge@glaxo.com organization: Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709, USA. susan_daluge@glaxo.com – sequence: 2 givenname: S S surname: Good fullname: Good, S S – sequence: 3 givenname: M B surname: Faletto fullname: Faletto, M B – sequence: 4 givenname: W H surname: Miller fullname: Miller, W H – sequence: 5 givenname: M H surname: St Clair fullname: St Clair, M H – sequence: 6 givenname: L R surname: Boone fullname: Boone, L R – sequence: 7 givenname: M surname: Tisdale fullname: Tisdale, M – sequence: 8 givenname: N R surname: Parry fullname: Parry, N R – sequence: 9 givenname: J E surname: Reardon fullname: Reardon, J E – sequence: 10 givenname: R E surname: Dornsife fullname: Dornsife, R E – sequence: 11 givenname: D R surname: Averett fullname: Averett, D R – sequence: 12 givenname: T A surname: Krenitsky fullname: Krenitsky, T A
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/9145874$$D View this record in MEDLINE/PubMed
BookMark	eNotkD1rwzAYhDWkpGnasWNBU6fYlRQpkscQ-gWBLs1sXstyoyJLriWn-N_XoZmO4x4O7m7QzAdvELqnJKeUqaftdpdzmoucEsVmaEHIZpNxRfg1uonxm0xeFGSO5gXlQkm-QB0VBTuoYoUB-3AyDmvoq6BH7azGftDOhGhrg8GDC1_416Yj7kIyPq1wNM7oZE_nNNnsOLTgsW3bwYfaNFZb4_WIT7YfIoYzaNN4i64acNHcXXSJDi_Pn7u3bP_x-r7b7jMQhKUMGIdNxVjNJJeN1vVaadWArKFpqJCsKKjmnMhGqWlrIbScuHUlBWighki2RI__vV0ffgYTU9naqI1z4E0YYikLQsSa8Al8uIBD1Zq67HrbQj-Wl4vYHzebaIk
CitedBy_id	crossref_primary_10_1080_15257770008035034 crossref_primary_10_2217_fmb_11_7 crossref_primary_10_1016_j_bmc_2005_05_007 crossref_primary_10_1016_j_tet_2004_10_034 crossref_primary_10_1002_ejic_201600853 crossref_primary_10_1016_j_tet_2013_01_011 crossref_primary_10_1007_BF02976674 crossref_primary_10_1002_cmdc_202000695 crossref_primary_10_1021_jo701332v crossref_primary_10_1081_NCN_51900 crossref_primary_10_1002_pds_3589 crossref_primary_10_1002_rmv_624 crossref_primary_10_1097_00002030_199816000_00002 crossref_primary_10_1080_15257770701296986 crossref_primary_10_2165_00003088_200443120_00004 crossref_primary_10_1097_00002030_199816000_00001 crossref_primary_10_1016_j_tet_2009_11_001 crossref_primary_10_1081_NCN_120006529 crossref_primary_10_1021_jo034999v crossref_primary_10_1016_j_ejmech_2016_04_034 crossref_primary_10_3389_fonc_2021_664794 crossref_primary_10_1081_DMR_200028812 crossref_primary_10_1081_SCC_120027249 crossref_primary_10_1177_095632020701800103 crossref_primary_10_1016_S0378_4347_98_00144_3 crossref_primary_10_1080_15257770701795839 crossref_primary_10_1146_annurev_pharmtox_010510_100228 crossref_primary_10_1177_2040206618813050 crossref_primary_10_1177_095632029800900406 crossref_primary_10_1177_095632020401500403 crossref_primary_10_1021_jm900492g crossref_primary_10_3389_fmicb_2018_00278 crossref_primary_10_32628_IJSRST251283 crossref_primary_10_1128_JVI_72_6_4858_4865_1998 crossref_primary_10_1542_peds_107_1_e4 crossref_primary_10_1002_ejoc_200400886 crossref_primary_10_1038_clpt_2008_236 crossref_primary_10_1007_BF02994766 crossref_primary_10_1002_hlca_200590099 crossref_primary_10_1081_NCN_120030720 crossref_primary_10_1016_S0040_4020_99_00424_X crossref_primary_10_1016_S0008_6215_03_00018_1 crossref_primary_10_1016_S0040_4039_02_01384_9 crossref_primary_10_3987_COM_99_8740 crossref_primary_10_1016_S0166_3542_99_00043_1 crossref_primary_10_1016_j_hivar_2012_02_003 crossref_primary_10_1097_QAD_0000000000000867 crossref_primary_10_1046_j_1469_0691_2000_00162_x crossref_primary_10_1016_j_reprotox_2015_07_070 crossref_primary_10_1139_v06_052 crossref_primary_10_1081_NCN_46786 crossref_primary_10_1016_S0040_4020_98_00320_2 crossref_primary_10_1016_j_bmc_2009_06_060 crossref_primary_10_1016_S0957_4166_02_00316_6 crossref_primary_10_1016_j_ejmech_2022_114554 crossref_primary_10_1007_s12010_016_2104_x crossref_primary_10_1002_med_21340 crossref_primary_10_1002_ardp_200400918 crossref_primary_10_1016_j_carres_2007_01_004 crossref_primary_10_1016_S0040_4020_01_01191_7 crossref_primary_10_1080_15257770701795813 crossref_primary_10_1592_phco_21_1_11_34439 crossref_primary_10_1016_j_cdc_2017_03_002 crossref_primary_10_1177_095632020401500502 crossref_primary_10_1097_00002030_200009080_00002 crossref_primary_10_1081_NCN_120006531 crossref_primary_10_1146_annurev_pharmtox_010611_134701 crossref_primary_10_1016_j_tetlet_2008_04_115 crossref_primary_10_1096_fj_07_8697rev crossref_primary_10_1016_S0960_894X_03_00330_5 crossref_primary_10_1097_QAD_0000000000001046 crossref_primary_10_1039_D4RA00304G crossref_primary_10_1128_AAC_46_1_135_143_2002 crossref_primary_10_1186_2046_4053_3_87 crossref_primary_10_1016_j_bcp_2013_07_012 crossref_primary_10_1021_jm060776w crossref_primary_10_1128_AAC_49_6_2504_2506_2005 crossref_primary_10_1016_j_antiviral_2007_03_005 crossref_primary_10_1128_AAC_43_7_1708 crossref_primary_10_1128_AAC_02012_12 crossref_primary_10_1016_S0022_3565_24_29461_1 crossref_primary_10_1007_s00253_007_0919_7 crossref_primary_10_1002_ejoc_202200708 crossref_primary_10_1016_j_febslet_2004_07_049 crossref_primary_10_1016_S0378_4347_99_00457_0 crossref_primary_10_1021_jo801848h crossref_primary_10_1128_AAC_48_4_1413_1415_2004 crossref_primary_10_1016_j_ejmech_2021_113467 crossref_primary_10_1007_BF02969417 crossref_primary_10_1016_S0040_4020_02_01053_0 crossref_primary_10_1097_00002030_200005050_00004 crossref_primary_10_1016_S0040_4020_03_00986_4 crossref_primary_10_3390_v16040593 crossref_primary_10_1016_S1359_6446_00_01558_0 crossref_primary_10_1097_00002030_200005050_00003 crossref_primary_10_1016_S0040_4020_02_01531_4 crossref_primary_10_1023_A_1011050209986 crossref_primary_10_1002_ejoc_201301033 crossref_primary_10_1016_j_tet_2011_03_054 crossref_primary_10_1016_S0040_4020_98_00471_2 crossref_primary_10_1021_jo802492g crossref_primary_10_1177_00912700122010096 crossref_primary_10_1128_AAC_48_8_2825_2830_2004 crossref_primary_10_1016_j_apsb_2012_10_001 crossref_primary_10_1002_ardp_200500118 crossref_primary_10_1086_322682 crossref_primary_10_1097_00007691_200208000_00015 crossref_primary_10_1021_jm990113x crossref_primary_10_1016_S1368_7646_98_80211_2 crossref_primary_10_1002_cpdd_996 crossref_primary_10_1080_15257770008035012 crossref_primary_10_1128_AAC_44_8_2061_2067_2000 crossref_primary_10_1016_j_cclet_2016_05_021 crossref_primary_10_1002_ejoc_201403642 crossref_primary_10_1128_AAC_43_6_1487 crossref_primary_10_1080_15257770008035015 crossref_primary_10_1007_s10822_010_9359_z crossref_primary_10_1128_AAC_49_5_1994_2001_2005 crossref_primary_10_1177_095632020301400104 crossref_primary_10_1542_peds_103_4_e47 crossref_primary_10_1128_AAC_43_12_2855 crossref_primary_10_1371_journal_pone_0123043 crossref_primary_10_2337_dc09_0177 crossref_primary_10_1002_cmdc_200900289 crossref_primary_10_1080_15257770_2019_1625380 crossref_primary_10_1007_s00216_017_0449_9 crossref_primary_10_1007_BF02972969 crossref_primary_10_1002_elps_200305425 crossref_primary_10_1016_S0040_4020_03_01074_3 crossref_primary_10_1002_jps_21047 crossref_primary_10_1002_chem_201002233 crossref_primary_10_1016_S1369_5274_98_80086_6 crossref_primary_10_1128_AAC_43_3_609 crossref_primary_10_1016_j_tetlet_2006_10_070 crossref_primary_10_1080_15257770008035008 crossref_primary_10_1002_cjoc_201300440 crossref_primary_10_1016_S0149_2918_02_85132_3 crossref_primary_10_1128_AAC_43_3_603 crossref_primary_10_1016_S0040_4039_02_00774_8 crossref_primary_10_1080_15257770600793869 crossref_primary_10_1021_jm061304k crossref_primary_10_1086_339751 crossref_primary_10_1002_ijc_24331 crossref_primary_10_1186_s12879_015_1183_6 crossref_primary_10_1080_15257770008033011 crossref_primary_10_1081_NCN_100002311 crossref_primary_10_1002_adsc_202000088 crossref_primary_10_1002_bmc_406 crossref_primary_10_1021_jo010224f crossref_primary_10_1016_S0166_3542_02_00103_1 crossref_primary_10_1016_j_bcp_2004_06_025 crossref_primary_10_1016_j_bmc_2011_05_026 crossref_primary_10_1016_j_bmc_2017_05_023 crossref_primary_10_1021_jm200650j crossref_primary_10_1128_AAC_01209_07 crossref_primary_10_1128_AAC_44_8_2052_2060_2000 crossref_primary_10_2165_00003088_200443150_00002 crossref_primary_10_1124_dmd_107_017723 crossref_primary_10_1189_jlb_68_3_345 crossref_primary_10_1371_journal_pone_0014221 crossref_primary_10_1016_j_tetlet_2011_02_036 crossref_primary_10_1080_15257770500379173 crossref_primary_10_1128_AAC_44_8_2093_2099_2000 crossref_primary_10_1016_S0166_3542_01_00150_4 crossref_primary_10_1128_AAC_49_11_4465_4473_2005 crossref_primary_10_1002_tcr_202100307 crossref_primary_10_1124_dmd_106_014274 crossref_primary_10_1002_ardp_200500154 crossref_primary_10_1021_jm000209n crossref_primary_10_1080_15257770802458246 crossref_primary_10_1097_00002030_199904160_00006 crossref_primary_10_1097_QAI_0000000000001660 crossref_primary_10_1021_cr030040w crossref_primary_10_1211_jpp_59_11_0001 crossref_primary_10_1002_rmv_454 crossref_primary_10_1016_S0753_3322_99_80063_8 crossref_primary_10_1016_j_tet_2010_11_097 crossref_primary_10_2174_0929867329666220718123153 crossref_primary_10_1177_135965350400900102 crossref_primary_10_1586_14787210_3_6_871 crossref_primary_10_1002_cmdc_201800361 crossref_primary_10_1081_NCN_120023272 crossref_primary_10_1080_14756360801906863 crossref_primary_10_1128_AAC_46_3_887_891_2002 crossref_primary_10_1002_ardp_200400875 crossref_primary_10_1128_AAC_45_1_138_144_2001 crossref_primary_10_1002_ejoc_202400181 crossref_primary_10_1021_jm0491400 crossref_primary_10_1081_NCN_100002528 crossref_primary_10_1097_QAI_0b013e31819ff0e6 crossref_primary_10_1002_bab_1814 crossref_primary_10_1021_jo0480601 crossref_primary_10_1016_S0378_4347_00_00619_8 crossref_primary_10_1128_JVI_01800_21 crossref_primary_10_1097_01_qai_0000137001_40505_56 crossref_primary_10_1016_j_jpba_2009_07_005 crossref_primary_10_1016_j_tet_2004_07_054 crossref_primary_10_1007_s11538_007_9234_9 crossref_primary_10_1097_00002030_199815000_00005 crossref_primary_10_1021_jm010418n crossref_primary_10_1128_AAC_46_11_3437_3446_2002 crossref_primary_10_1081_NCN_120003289 crossref_primary_10_1002_chem_200400079 crossref_primary_10_1016_j_toxlet_2013_10_036 crossref_primary_10_1016_S0169_409X_99_00023_X crossref_primary_10_1016_S0960_894X_02_00841_7 crossref_primary_10_1097_00126334_200303010_00003 crossref_primary_10_1592_phco_19_11_932_31568 crossref_primary_10_1016_j_tetlet_2007_01_016 crossref_primary_10_1097_00002030_199814000_00004 crossref_primary_10_1128_CMR_00102_15 crossref_primary_10_1016_S0040_4039_99_00497_9 crossref_primary_10_1042_BCJ20160772 crossref_primary_10_1128_AAC_43_8_1835 crossref_primary_10_1021_jo8003277 crossref_primary_10_1021_jm9901327 crossref_primary_10_1186_1471_2334_5_98 crossref_primary_10_1016_S0166_3542_01_00190_5 crossref_primary_10_1128_AAC_47_6_1936_1942_2003 crossref_primary_10_1080_15257770802400065 crossref_primary_10_1002_biot_200800302 crossref_primary_10_1038_srep42824 crossref_primary_10_1081_NCN_51898 crossref_primary_10_1021_jo200670v crossref_primary_10_1081_NCN_120039252 crossref_primary_10_1016_j_ijbiomac_2021_01_076 crossref_primary_10_1128_AAC_46_1_89_94_2002 crossref_primary_10_1128_AAC_44_6_1686_1690_2000 crossref_primary_10_1016_S0022_1759_98_00101_X crossref_primary_10_2217_17584310_3_1_19 crossref_primary_10_1021_jm020246 crossref_primary_10_1007_s10593_021_02912_8 crossref_primary_10_1128_JVI_78_10_5390_5401_2004 crossref_primary_10_1097_00002030_199907300_00027 crossref_primary_10_1067_mpd_2002_125007 crossref_primary_10_1016_j_antiviral_2018_04_004 crossref_primary_10_1086_376991 crossref_primary_10_1212_WNL_54_2_379 crossref_primary_10_1081_NCN_120021965 crossref_primary_10_1002_ajoc_201600154 crossref_primary_10_1080_07328319908044879 crossref_primary_10_1007_s101560100024 crossref_primary_10_1002_bmc_1612 crossref_primary_10_1016_j_antiviral_2006_03_012 crossref_primary_10_1097_QAD_0b013e32833676eb crossref_primary_10_1016_S0957_4166_00_00482_1 crossref_primary_10_1080_17512433_2020_1782737 crossref_primary_10_1002_pauz_19980270306 crossref_primary_10_1002_ajoc_201500517 crossref_primary_10_1016_j_bmcl_2004_01_108 crossref_primary_10_1002_ejoc_201301097 crossref_primary_10_1097_01_inf_0000246976_40494_af crossref_primary_10_1080_15257770_2018_1500697 crossref_primary_10_1016_j_bmc_2006_10_043 crossref_primary_10_1016_S0026_895X_24_26468_3 crossref_primary_10_1097_00002030_200001280_00012 crossref_primary_10_1097_00002030_200307040_00008 crossref_primary_10_7759_cureus_48229 crossref_primary_10_4155_fmc_2018_0324 crossref_primary_10_1016_j_tet_2006_07_050 crossref_primary_10_1021_jo991212l
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/AAC.41.5.1082
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Biology Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID	9145874
Genre	Journal Article
GroupedDBID	--- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ 7X8 AAGFI
ID	FETCH-LOGICAL-a502t-a24a6b22d2747fccd38c8fa7daff1572991c4407f8810895c77473b75aca1e072
IEDL.DBID	7X8
ISICitedReferencesCount	388
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10.1128/AAC.41.5.1082&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0066-4804
IngestDate	Thu Oct 02 11:00:47 EDT 2025 Sat Sep 28 07:36:24 EDT 2024
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a502t-a24a6b22d2747fccd38c8fa7daff1572991c4407f8810895c77473b75aca1e072
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://aac.asm.org/content/aac/41/5/1082.full.pdf
PMID	9145874
PQID	79005304
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_79005304 pubmed_primary_9145874
PublicationCentury	1900
PublicationDate	1997-05-01
PublicationDateYYYYMMDD	1997-05-01
PublicationDate_xml	– month: 05 year: 1997 text: 1997-05-01 day: 01
PublicationDecade	1990
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Antimicrobial agents and chemotherapy
PublicationTitleAlternate	Antimicrob Agents Chemother
PublicationYear	1997
References	2159703 - Am J Med. 1990 May 21;88(5B):11S-15S 8092819 - Antimicrob Agents Chemother. 1994 Jun;38(6):1230-8 6314892 - Antimicrob Agents Chemother. 1983 Sep;24(3):370-4 3299090 - N Engl J Med. 1987 Jul 23;317(4):192-7 1708977 - Antimicrob Agents Chemother. 1991 Feb;35(2):322-8 1400293 - J Biol Chem. 1992 Oct 5;267(28):19792-7 1133682 - J Pharm Sci. 1975 Jan;64(1):112-4 7861015 - J Infect Dis. 1995 Mar;171 Suppl 2:S113-7 1970466 - Ann Intern Med. 1990 May 15;112(10):727-37 2767322 - Exp Cell Biol. 1989;57(2):53-9 7518218 - Antimicrob Agents Chemother. 1994 Apr;38(4):868-71 1981516 - Drug Metab Dispos. 1990 Nov-Dec;18(6):1078-83 7685907 - Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653-6 1713216 - J Biol Chem. 1991 Jul 25;266(21):14128-34 2334156 - Antimicrob Agents Chemother. 1990 Mar;34(3):436-41 7685993 - Antimicrob Agents Chemother. 1993 May;37(5):1004-9 7540846 - AIDS. 1995 Apr;9(4):351-7 2554751 - Anal Biochem. 1989 Aug 1;180(2):222-6 8834914 - Antimicrob Agents Chemother. 1996 Feb;40(2):514-9 3367302 - J Pharmacol Exp Ther. 1988 May;245(2):466-70 2062804 - Pharm Res. 1991 Jun;8(6):739-43 2088205 - Antiviral Res. 1990 Oct-Nov;14(4-5):181-205 1703154 - J Biol Chem. 1991 Jan 25;266(3):1754-62 1981517 - Drug Metab Dispos. 1990 Nov-Dec;18(6):1084-91 8595505 - J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S28-33 1845891 - J Virol. 1991 Jan;65(1):308-12 6351865 - Biochem Pharmacol. 1983 Sep 1;32(17):2505-9 2110596 - J Virol. 1990 Jun;64(6):2660-8 7526782 - Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603 7695285 - Antimicrob Agents Chemother. 1994 Dec;38(12):2921-4 8585767 - Antiviral Res. 1995 Oct;28(2):133-46 1716788 - Science. 1991 Sep 27;253(5027):1557-9 517739 - Anal Biochem. 1979 Nov 1;99(2):268-73 2847711 - Biochem Biophys Res Commun. 1988 Oct 31;156(2):1046-53 2497128 - J Virol Methods. 1989 Mar;23(3):263-76 8384813 - Antimicrob Agents Chemother. 1993 Mar;37(3):441-7 9145875 - Antimicrob Agents Chemother. 1997 May;41(5):1094-8 9145876 - Antimicrob Agents Chemother. 1997 May;41(5):1099-107 7861018 - J Infect Dis. 1995 Mar;171 Suppl 2:S131-9 1374638 - Biochemistry. 1992 May 12;31(18):4473-9 2764535 - Antimicrob Agents Chemother. 1989 Jun;33(6):844-9 1975038 - Lancet. 1990 Sep 1;336(8714):526-9 1316140 - Br J Haematol. 1992 Apr;80(4):437-45 2306735 - Cancer Res. 1990 Mar 15;50(6):1817-21 1383219 - J Biol Chem. 1992 Oct 15;267(29):21220-4 3471758 - J Biol Chem. 1987 Apr 25;262(12):5748-54 6968622 - Cancer Treat Rep. 1980 Apr-May;64(4-5):629-33 2209763 - Exp Hematol. 1990 Nov;18(10):1094-6
References_xml	– reference: 2088205 - Antiviral Res. 1990 Oct-Nov;14(4-5):181-205 – reference: 2847711 - Biochem Biophys Res Commun. 1988 Oct 31;156(2):1046-53 – reference: 2764535 - Antimicrob Agents Chemother. 1989 Jun;33(6):844-9 – reference: 1981517 - Drug Metab Dispos. 1990 Nov-Dec;18(6):1084-91 – reference: 8092819 - Antimicrob Agents Chemother. 1994 Jun;38(6):1230-8 – reference: 2497128 - J Virol Methods. 1989 Mar;23(3):263-76 – reference: 6314892 - Antimicrob Agents Chemother. 1983 Sep;24(3):370-4 – reference: 2159703 - Am J Med. 1990 May 21;88(5B):11S-15S – reference: 7526782 - Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603 – reference: 2767322 - Exp Cell Biol. 1989;57(2):53-9 – reference: 3367302 - J Pharmacol Exp Ther. 1988 May;245(2):466-70 – reference: 1713216 - J Biol Chem. 1991 Jul 25;266(21):14128-34 – reference: 2209763 - Exp Hematol. 1990 Nov;18(10):1094-6 – reference: 7685907 - Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653-6 – reference: 9145875 - Antimicrob Agents Chemother. 1997 May;41(5):1094-8 – reference: 2334156 - Antimicrob Agents Chemother. 1990 Mar;34(3):436-41 – reference: 1400293 - J Biol Chem. 1992 Oct 5;267(28):19792-7 – reference: 7518218 - Antimicrob Agents Chemother. 1994 Apr;38(4):868-71 – reference: 8595505 - J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S28-33 – reference: 7861015 - J Infect Dis. 1995 Mar;171 Suppl 2:S113-7 – reference: 7540846 - AIDS. 1995 Apr;9(4):351-7 – reference: 2306735 - Cancer Res. 1990 Mar 15;50(6):1817-21 – reference: 2554751 - Anal Biochem. 1989 Aug 1;180(2):222-6 – reference: 1716788 - Science. 1991 Sep 27;253(5027):1557-9 – reference: 3299090 - N Engl J Med. 1987 Jul 23;317(4):192-7 – reference: 1845891 - J Virol. 1991 Jan;65(1):308-12 – reference: 517739 - Anal Biochem. 1979 Nov 1;99(2):268-73 – reference: 1970466 - Ann Intern Med. 1990 May 15;112(10):727-37 – reference: 6351865 - Biochem Pharmacol. 1983 Sep 1;32(17):2505-9 – reference: 1708977 - Antimicrob Agents Chemother. 1991 Feb;35(2):322-8 – reference: 1703154 - J Biol Chem. 1991 Jan 25;266(3):1754-62 – reference: 7695285 - Antimicrob Agents Chemother. 1994 Dec;38(12):2921-4 – reference: 1975038 - Lancet. 1990 Sep 1;336(8714):526-9 – reference: 1133682 - J Pharm Sci. 1975 Jan;64(1):112-4 – reference: 7861018 - J Infect Dis. 1995 Mar;171 Suppl 2:S131-9 – reference: 9145876 - Antimicrob Agents Chemother. 1997 May;41(5):1099-107 – reference: 3471758 - J Biol Chem. 1987 Apr 25;262(12):5748-54 – reference: 1374638 - Biochemistry. 1992 May 12;31(18):4473-9 – reference: 2062804 - Pharm Res. 1991 Jun;8(6):739-43 – reference: 1981516 - Drug Metab Dispos. 1990 Nov-Dec;18(6):1078-83 – reference: 1383219 - J Biol Chem. 1992 Oct 15;267(29):21220-4 – reference: 8384813 - Antimicrob Agents Chemother. 1993 Mar;37(3):441-7 – reference: 8585767 - Antiviral Res. 1995 Oct;28(2):133-46 – reference: 8834914 - Antimicrob Agents Chemother. 1996 Feb;40(2):514-9 – reference: 2110596 - J Virol. 1990 Jun;64(6):2660-8 – reference: 1316140 - Br J Haematol. 1992 Apr;80(4):437-45 – reference: 6968622 - Cancer Treat Rep. 1980 Apr-May;64(4-5):629-33 – reference: 7685993 - Antimicrob Agents Chemother. 1993 May;37(5):1004-9
SSID	ssj0006590
Score	2.0905435
Snippet	1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1082
SubjectTerms	Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - metabolism Adenosine Deaminase - metabolism Administration, Oral Animals Anti-HIV Agents - blood Anti-HIV Agents - chemistry Anti-HIV Agents - pharmacokinetics Anti-HIV Agents - urine Antiviral Agents - blood Antiviral Agents - pharmacokinetics Area Under Curve Biotransformation Cells, Cultured Dideoxynucleosides - blood Dideoxynucleosides - chemistry Dideoxynucleosides - pharmacokinetics Dideoxynucleosides - urine Drug Resistance, Microbial Female Half-Life HIV-1 - drug effects Humans Injections, Intravenous Macaca fascicularis Male Rats Structure-Activity Relationship
Title	1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
URI	https://www.ncbi.nlm.nih.gov/pubmed/9145874 https://www.proquest.com/docview/79005304
Volume	41
WOSCitedRecordID	wos10.1128/AAC.41.5.1082&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NaxsxEB3SpC259MNtaNKm1aHkZCXelWRJUCgmJPTQGB8S8M1o9QELYdf1Ogb_-8zsevGp9NDLXsTCMjsavZnRvAfw3afMZyFZ7oIJXAYjuJWKUhVRpIQZdBy3g8K_9XRq5nM7O4Af_SwMXavsY2IbqEPtqUZ-pS35y0j-XP7hpBlFvdWdgMYLOBIIZMin9XzPFT5WXYUFD1UuzUj2DJu5uZpMri9ldqnohl3-d2zZnjG3b__v697Bmx22ZJPOGd7DQawG8KpTm9wO4PXdro8-gItZx1i9HbL7_QBWM2QXbLbnst5-gCXikPzB2CFzrKo38ZF5typqv_WPpWcVkSHXJPjJXEVVIEZlXbasEYivh6xpNXYwnOLquuStHCAraSClDpGYK2jsk23K1VPDaL6CZCw-wsPtzf31L74TaeBOjfI1d7l04yLPA6W3yfsgjDfJ6eBSyhRCd5t5iVljMgaNbZVHvKlFoZXzLosjnZ_AYVVX8RMwgfFmXAhcoSRNWGMTGlWGqKMIhTKn8K03_gI3AXU2XBXrp2bRm_8UTrr_t1h2XB0Lm0lltDz756uf4bhjpqW7jF_gKOHuj-fw0m_WZbP62roWPqezu2ezS9le
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=1592U89%2C+a+novel+carbocyclic+nucleoside+analog+with+potent%2C+selective+anti-human+immunodeficiency+virus+activity&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Daluge%2C+S+M&rft.au=Good%2C+S+S&rft.au=Faletto%2C+M+B&rft.au=Miller%2C+W+H&rft.date=1997-05-01&rft.issn=0066-4804&rft.volume=41&rft.issue=5&rft.spage=1082&rft_id=info:doi/10.1128%2FAAC.41.5.1082&rft_id=info%3Apmid%2F9145874&rft_id=info%3Apmid%2F9145874&rft.externalDocID=9145874
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon